503597-15-7

Basic information

• Product Name: N-[4-(4-tert-butylphenyl)-2-(pivaloyloxymethyl)butyl]-N'-[3-methoxy-4-(methoxymethoxy)benzyl]thiourea
• Synonyms: N-[4-(4-tert-butylphenyl)-2-(pivaloyloxymethyl)butyl]-N'-[3-methoxy-4-(methoxymethoxy)benzyl]thiourea
• CAS NO: 503597-15-7
• Molecular Weight: 558.783
• Mol File: 503597-15-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-[4-(4-tert-butylphenyl)-2-(pivaloyloxymethyl)butyl]-N'-[3-methoxy-4-(methoxymethoxy)benzyl]thiourea(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(4-tert-butylphenyl)-2-(pivaloyloxymethyl)butyl]-N'-[3-methoxy-4-(methoxymethoxy)benzyl]thiourea(503597-15-7)
• EPA Substance Registry System: N-[4-(4-tert-butylphenyl)-2-(pivaloyloxymethyl)butyl]-N'-[3-methoxy-4-(methoxymethoxy)benzyl]thiourea(503597-15-7)

Safety Data

• Hazardous Substances Data: 503597-15-7(Hazardous Substances Data)

Upstream product

• 503597-13-5 2,2-dimethyl-propionic acid 2-aminomethyl-4-(4-tert-butyl-phenyl)-butyl ester 
• 289903-62-4 4-[(methoxylmethyl)oxy]-3-methoxybenzyl isothiocyanate 
• 5406-86-0 2-(4-tert-butylphenyl)ethanol 
• 56829-61-9 1-(2-bromoethyl)-4-(tert-butyl)benzene 
• 1746-23-2 4-tert-Butylstyrene 
• 503597-12-4 2-(azidomethyl)-4-(4-tert-butylphenyl)butyl pivalate 
• 503597-06-6 diethyl 2-(4-tert-butylphenethyl)malonate 
• 503597-10-2 4-(4-tert-butylphenyl)-2-(hydroxymethyl)butyl pivalate 
• 503597-08-8 2-(4-tert-butylphenethyl)-1,3-propanediol 

Relevant articles and documents

Structure-activity relationships of simplified resiniferatoxin analogues with potent VR1 agonism elucidates an active conformation of RTX for VR1 binding

We previously described a series of N-(3-acyloxy-2-benzylpropyl) homovanillate and N′-(4-hydroxy-3-methoxybenzyl) thiourea derivatives that were potent VR1 agonists with high-affinities and excellent analgesic profiles. The design of these simplified RTX analogues was based on our RTX-derived pharmacophore model which incorporates the 4-hydroxy-3- methoxyphenyl (A-region), C20-ester (B-region), orthophenyl (C1-region) and C3-keto (C2-region) groups of RTX. For the purpose of optimizing the spatial arrangement of the four principal pharmacophores on the lead agonists (1-4), we have modified the distances in the parent C-region, 3-acyloxy-2-benzylpropyl groups, by lengthening or shortening one carbon to vary the distances between the pharmacophores. We find that two of the amides, 4 and 19, possess EC50 values i) and calcium influx (EC50) values. The binding affinities of the agonists correlated best with the RMS values derived from RTX conformation E (r2=0.92), predicting a model of the active conformation of RTX and related vanilloids for binding to VR1. Poorer correlation was obtained between any of the conformations and the EC 50 values for calcium influx.